Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Dixon, M. [3 ]
Taylor, F. [4 ]
Sun, X. [4 ]
Yip, C. [4 ]
Blum, S. I. [5 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Lawrenceville, GA USA
[4] Adelphi Values LLC, Patient Centered Outcomes, Boston, MA USA
[5] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.958
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437P
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [41] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year followup from CheckMate 142
    Andre, T.
    Lonardi, S.
    Wong, K.
    Lenz, H.
    Gelsomino, F.
    Aglietta, M.
    Morse, M.
    Van Cutsem, E.
    McDermott, R.
    Hill, A.
    Sawyer, M.
    Hendlisz, A.
    Neyns, B.
    Abdullaev, S.
    Memaj, A.
    Lei, M.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S213 - S214
  • [42] Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.
    Sinicrope, Frank A.
    Chakrabarti, Sakti
    Eiring, Rachel
    Mitchelll, Jessica L.
    Finnes, Heidi D.
    Hubbard, Joleen Marie
    McWilliams, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI)
    Deverly, Sarah Blanchet
    Raffy, Balthazar
    Ratovomanana, Toky
    Nicolle, Remy
    Nay, Paula
    Andre, Thierry
    Duval, Alex
    Cohen, Romain
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 272 - 272
  • [44] One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Meurisse, Aurelia
    Pudlarz, Thomas
    Bennouna, Jaafar
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Menu, Yves
    Vernerey, Dewi
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Nivolumab plus ipilimumab in microsatellite instability high (MSI)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study
    Depotte, L.
    Nay, P.
    Borg, C.
    Meurisse, A.
    Henriques, J.
    Bennouna, J.
    de la Fouchardiere, C.
    Tougeron, D.
    Mazard, T.
    Chibaudel, B.
    Tournigand, C.
    Vernerey, D.
    Pigneur, F.
    Andre, T.
    Cohen, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S453 - S454
  • [47] Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).
    Svrcek, Magali
    Colle, Raphael
    Cayre, Anne
    Bourgoin, Pierre
    Cohen, Romain
    Andre, Thierry
    Penault-Llorca, Frederique Madeleine
    Radosevic-Robin, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    Andre, T.
    Lonardi, S.
    Wong, K. Y. M.
    Lenz, H. -J
    Gelsomino, F.
    Aglietta, M.
    Van Cutsem, E.
    McDermott, R.
    Hill, A.
    Sawyer, M. B.
    Hendlisz, A.
    Neyns, B.
    Abdullaev, S.
    Memaj, A.
    Lei, M.
    Dixon, M.
    Kopetz, S.
    Overman, M. J.
    Morse, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 1052 - 1060
  • [50] Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.
    Kawazoe, Akihito
    Shitara, Kohei
    Noguchi, Masaaki
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345